Compensation award — excluded from discretionary-purchase analysis.
Loading…
Reporting person on SEC Form 4
Jennifer L Taubert
Jennifer L Taubert is Director at Johnson & Johnson. OQRO lists 22 transactions filed with the SEC under this name, the latest on Oct 2, 2026, each linked to the official Form 4.
Director
Disclosures on record
22
Companies involved
2
Disclosure history
Officer sold
~$3.95MReported value · 15K sh @ $263.36
Stock since the trade -3.6% · S&P 500 +0.3% · to Oct 5
Johnson & Johnson's WWC. Innovative Medicine sold $3.95M of Johnson & Johnson shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.